PHAXIAM Therapeutics S.A. Net Income

PHAXIAM Therapeutics S.A. (PHXM) currently reports a net income of $-11M as of December 2023. That compares with $-18M in the prior-year period — up 39.9% year over year. That is below the Healthcare sector average of $16B. Use the charts on this page to explore PHAXIAM Therapeutics S.A.'s net income history and peer comparisons.

PHAXIAM Therapeutics S.A.'s net income increased from $-18M to $-11M — a 39.9% year-over-year increase (period ending December 2023). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

PHAXIAM Therapeutics S.A.'s net income of $-11M is lower than the Healthcare sector average of $16B. That is roughly 100.1% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

PHAXIAM Therapeutics S.A. reported $-11M in net income as of December 2023. That compares with $-18M in the prior-year period — up 39.9% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current net income of $-11M, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is $16B. From there, open related valuation or income-statement pages for PHAXIAM Therapeutics S.A., and consider following PHXM for alerts when major investors trade the stock.